Merck & Co. Inc. (MRK)

85.06
NYSE : Health Technology
Prev Close 83.46
Day Low/High 84.15 / 85.36
52 Wk Low/High 66.10 / 87.07
Avg Volume 9.94M
Exchange NYSE
Shares Outstanding 2.56B
Market Cap 213.69B
EPS 2.30
P/E Ratio 39.37
Div & Yield 2.20 (2.55%)
Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #7 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #93 spot out of 500.

The Technical Oracle of Delphi Says Merck Could Go Up or Down

The Technical Oracle of Delphi Says Merck Could Go Up or Down

How do the charts and indicators look ahead of their quarterly release?

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

Merck and Pfizer have been laggards so far in 2019. Technical warnings occurred on Dec. 4 when both set multiyear highs and both received downgrades.

The Market Starts Rotating: Cramer's 'Mad Money' Recap (Thursday 1/24/19)

The Market Starts Rotating: Cramer's 'Mad Money' Recap (Thursday 1/24/19)

Thursday's market action showed signs investors are moving away from safety plays, Jim Cramer says.

Merck To Hold Fourth-Quarter And Full-Year 2018 Sales And Earnings Conference Call On February 1

Merck To Hold Fourth-Quarter And Full-Year 2018 Sales And Earnings Conference Call On February 1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Merck's KEYTRUDA® (pembrolizumab) Reduced Risk Of Death By 31 Percent Compared To Chemotherapy In Previously Treated Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Merck's KEYTRUDA® (pembrolizumab) Reduced Risk Of Death By 31 Percent Compared To Chemotherapy In Previously Treated Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the second-line treatment of...

Moderna Shares Jump on Positive Cancer-Treatment Progress

Moderna Shares Jump on Positive Cancer-Treatment Progress

Report on positive results of new drugs to treat ovarian and other cancers sends shares higher.

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Jim Cramer talks about the Fed, and outlines your game plan.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Merck Is My Top Stock Pick for 2019

Merck Is My Top Stock Pick for 2019

People will still take their medicine regardless of the state of the economy.

Merck's KEYTRUDA® (pembrolizumab) Receives Five New Approvals In Japan, Including In Advanced Non-Small Cell Lung Cancer (NSCLC), As Adjuvant Therapy For Melanoma, And In Advanced Microsatellite Instability-High (MSI-H) Tumors

Merck's KEYTRUDA® (pembrolizumab) Receives Five New Approvals In Japan, Including In Advanced Non-Small Cell Lung Cancer (NSCLC), As Adjuvant Therapy For Melanoma, And In Advanced Microsatellite Instability-High (MSI-H) Tumors

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that KEYTRUDA, Merck's anti-PD-1 therapy, has simultaneously received five new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA), including...

Merck Exercises Option For NGM Bio's Investigational Insulin Sensitizer, NGM313, For The Treatment Of NASH And Type 2 Diabetes

Merck Exercises Option For NGM Bio's Investigational Insulin Sensitizer, NGM313, For The Treatment Of NASH And Type 2 Diabetes

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc.

Pfizer Could Be a Healthy Option in This Volatile Market

Pfizer Could Be a Healthy Option in This Volatile Market

The health care sector may a good place to weather this storm. Here is why and how to play it.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Merck To Participate At The 37th Annual J.P. Morgan Healthcare Conference

Merck To Participate At The 37th Annual J.P. Morgan Healthcare Conference

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

The New #64 Most Shorted S&P 500 Component: Merck

The New #64 Most Shorted S&P 500 Component: Merck

The most recent short interest data has been released for the 12/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck Provides Update On KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) For KEYNOTE-042 Trial

Merck Provides Update On KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) For KEYNOTE-042 Trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

LYNPARZA® (olaparib) Meets Primary Endpoint In Phase 3 SOLO-3 Trial For The Treatment Of Relapsed BRCA-Mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Meets Primary Endpoint In Phase 3 SOLO-3 Trial For The Treatment Of Relapsed BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the randomized, open-label, controlled, Phase 3 SOLO-3 trial of LYNPARZA tablets in 266 patients with relapsed ovarian cancer after...

LYNPARZA® (olaparib) Approved By FDA For First-Line Maintenance Therapy In BRCA-Mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Approved By FDA For First-Line Maintenance Therapy In BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy For Adults With Resected Stage III Melanoma

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy For Adults With Resected Stage III Melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node...

Merck Slips After Announcing Acquisition of France's Antelliq Group

Merck Slips After Announcing Acquisition of France's Antelliq Group

Merck buys French digital animal identification solutions company Antelliq Group.

Jim Cramer: What to Buy in This Treacherous Market

Jim Cramer: What to Buy in This Treacherous Market

Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.

Merck To Acquire Privately Held Antelliq Group

Merck To Acquire Privately Held Antelliq Group

Merck [NYSE:MRK], known as MSD outside the United States and Canada, and privately held Antelliq Group today announced that the companies have signed a definitive agreement under which Merck will acquire Antelliq from funds advised by BC Partners.

Merck And Instituto Butantan Announce Collaboration Agreement To Develop Vaccines To Protect Against Dengue Infections

Merck And Instituto Butantan Announce Collaboration Agreement To Develop Vaccines To Protect Against Dengue Infections

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Instituto Butantan, Sao Paulo, Brazil, a non-profit producer of immunobiologic products for Brazil today announced a collaboration agreement to develop vaccines to protect against...

TheStreet Quant Rating: A+ (Buy)